Seemingly rebuilding on the endeavor that had previously been in San Francisco and appeared to have been close down, management re-entered the SBIR arena in 2017. That recent effort organized around use of "physiologic" hematopoietic stem cells (naturally occurring stem cells from the bone marrow or blood. Not human embryonic, huES, or induced pluipotent, iPS, stem cells) from the patient to treat vascular damage in the eye, the heart and peripheral vessels, primarily as a result of chronic diabetes. Ex vivo, transiently modified human autologous peripheral blood, bone marrow and cord blood hematopoietic stem cells. Google lists the firm (2019) as permanently closed and the website is gone.
